[go: up one dir, main page]

SG11201810983PA - Novel heterocyclic derivatives useful as shp2 inhibitors - Google Patents

Novel heterocyclic derivatives useful as shp2 inhibitors

Info

Publication number
SG11201810983PA
SG11201810983PA SG11201810983PA SG11201810983PA SG11201810983PA SG 11201810983P A SG11201810983P A SG 11201810983PA SG 11201810983P A SG11201810983P A SG 11201810983PA SG 11201810983P A SG11201810983P A SG 11201810983PA SG 11201810983P A SG11201810983P A SG 11201810983PA
Authority
SG
Singapore
Prior art keywords
bybp
kechuang
beijing
street
building
Prior art date
Application number
SG11201810983PA
Inventor
Cunbo Ma
Panliang Gao
Jie Chu
Xinping Wu
Chunwei Wen
Di Kang
Jinlong Bai
Xiaoyan Pei
Original Assignee
Jacobio Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jacobio Pharmaceuticals Co Ltd filed Critical Jacobio Pharmaceuticals Co Ltd
Publication of SG11201810983PA publication Critical patent/SG11201810983PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111110111101110111111110101111100111111111111111100111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/211303 Al 14 December 2017 (14.12.2017) WIP0 I PCT (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CO7D 401/14 (2006.01) A61K 31/537 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, CO7D 401/04 (2006.01) A61P 35/00 (2006.01) DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, CO7D 471/10 (2006.01) A61P 9/00 (2006.01) HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, CO7D 491/107 (2006.01) A61P 19/00 (2006.01) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, CO7D 498/10 (2006.01) A61P 21/00 (2006.01) MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, A61K 31/506 (2006.01) PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (21) International Application Number: SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, PCT/CN2017/087471 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 07 June 2017 (07.06.2017) kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (25) Filing Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (26) Publication Language: English TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (30) Priority Data: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/CN2016/085122 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 07 June 2016 (07.06.2016) CN KM, ML, MR, NE, SN, TD, TG). (71) Applicant: JACOBIO PHARMACEUTICALS CO., Published: LTD. [CN/CN]; Unit 2, Building 5, BYBP, No.88 — with international search report (Art. 21(3)) Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). (72) Inventors: MA, Cunbo; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). GAO, Panliang; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Develop- ment Area, Daxing, Beijing 101111 (CN). CHU, Jie; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). WU, Xinping; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). WEN, Chunwei; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Dax- ing, Beijing 101111 (CN). KANG, Di; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). BAI, Jinlong; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). PEI, Xi- aoyan; Unit 2, Building 5, BYBP, No.88 Kechuang Street 6th, Business Development Area, Daxing, Beijing 101111 (CN). Designated States (unless otherwise indicated, for every = (81) kind of national protection available): AE, AG, AL, AM, Il (54) en en Il Title: NOVEL HETEROCYCLIC DERIVATIVES USEFUL AS SHP2 INHIBITORS (57) : Provided are certain pyrazine derivatives (I) as SHP2 in- R4 hibitors which is shown as formula (I), their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided are fused Il e , ' Y 2 R3,„„.• .\ x heterocyclic derivatives useful as inhibitors of SHP2, methods for produc- .„./'-' ''',„,,,,. N Ir . \"' Il ei 1 ing such compounds and methods for treating SHP2-mediated disorder. a 1 (1) R5 C
SG11201810983PA 2016-06-07 2017-06-07 Novel heterocyclic derivatives useful as shp2 inhibitors SG11201810983PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2016085122 2016-06-07
PCT/CN2017/087471 WO2017211303A1 (en) 2016-06-07 2017-06-07 Novel heterocyclic derivatives useful as shp2 inhibitors

Publications (1)

Publication Number Publication Date
SG11201810983PA true SG11201810983PA (en) 2019-01-30

Family

ID=60578379

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202110874TA SG10202110874TA (en) 2016-06-07 2017-06-07 Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201810983PA SG11201810983PA (en) 2016-06-07 2017-06-07 Novel heterocyclic derivatives useful as shp2 inhibitors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202110874TA SG10202110874TA (en) 2016-06-07 2017-06-07 Novel heterocyclic derivatives useful as shp2 inhibitors

Country Status (23)

Country Link
US (1) US10858359B2 (en)
EP (2) EP3464272B1 (en)
JP (3) JP6751203B2 (en)
KR (5) KR20210141778A (en)
CN (3) CN114539273A (en)
AU (1) AU2017276457B2 (en)
CA (1) CA3026784A1 (en)
CY (1) CY1125042T1 (en)
DK (1) DK3464272T3 (en)
EA (3) EA202092442A3 (en)
ES (1) ES2908801T3 (en)
HR (1) HRP20220251T1 (en)
HU (1) HUE057838T2 (en)
LT (1) LT3464272T (en)
MA (1) MA45189A (en)
MX (3) MX388576B (en)
PH (1) PH12018550202A1 (en)
PL (1) PL3464272T3 (en)
PT (1) PT3464272T (en)
RS (1) RS62987B1 (en)
SG (2) SG10202110874TA (en)
SI (1) SI3464272T1 (en)
WO (1) WO2017211303A1 (en)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11466017B2 (en) 2011-03-10 2022-10-11 Board Of Regents, The University Of Texas System Heterocyclic inhibitors of PTPN11
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
CN114539273A (en) 2016-06-07 2022-05-27 北京加科思新药研发有限公司 Novel heterocyclic derivatives useful as SHP2 inhibitors
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
TW202500565A (en) 2016-10-24 2025-01-01 美商傳達治療有限公司 Shp2 phosphatase inhibitors and methods of use thereof
BR112019014527A2 (en) 2017-01-23 2020-02-27 Revolution Medicines, Inc. PYRIDINE COMPOUNDS AS ALLOSTIC SHP2 INHIBITORS
AR110740A1 (en) 2017-01-23 2019-05-02 Revolution Medicines Inc BICYCLIC COMPOUNDS AS SHP2 ALOSTERIC INHIBITORS
HRP20241239T1 (en) * 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
WO2018218133A1 (en) 2017-05-26 2018-11-29 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
JP7356414B2 (en) 2017-09-07 2023-10-04 レヴォリューション・メディスンズ，インコーポレイテッド SHP2 inhibitor compositions and methods for treating cancer
MA50245A (en) 2017-09-11 2020-07-22 Krouzon Pharmaceuticals Inc OCTAHYDROCYCLOPENTA ALLOSTERIC INHIBITORS [C] SHP2 PYRROLE
WO2019067843A1 (en) 2017-09-29 2019-04-04 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors
CN111212834B (en) 2017-10-12 2024-01-19 锐新医药公司 Pyridine, pyrazine and triazine compounds as allosteric SHP2 inhibitors
BR112020009757A2 (en) 2017-12-15 2020-11-03 Revolution Medicines, Inc. polycyclic compounds as allosteric inhibitors of shp2
EP3753941B1 (en) 2018-02-13 2024-05-01 Shanghai Blueray Biopharma Co., Ltd. Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
JP7326305B2 (en) 2018-03-02 2023-08-15 大塚製薬株式会社 pharmaceutical compound
KR102724968B1 (en) 2018-03-21 2024-10-31 수조우 푸허 바이오파마 컴퍼니 리미티드 SHP2 inhibitors and uses thereof
SG11202009245TA (en) 2018-03-21 2020-10-29 Relay Therapeutics Inc Shp2 phosphatase inhibitors and methods of use thereof
WO2019183364A1 (en) 2018-03-21 2019-09-26 Relay Therapeutics, Inc. Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
SG11202009793TA (en) 2018-04-10 2020-10-29 Revolution Medicines Inc Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations
EP3787627A4 (en) 2018-05-02 2021-12-01 Navire Pharma, Inc. SUBSTITUTED HETEROCYCLIC INHIBITORS OF PTPN11
CN115721648A (en) * 2018-05-09 2023-03-03 北京加科思新药研发有限公司 Novel heterocyclic derivatives useful as SHP2 inhibitors
EP3827009A4 (en) 2018-07-24 2022-04-27 Taiho Pharmaceutical Co., Ltd. HETEROBICYCLIC COMPOUNDS TO INHIBIT SHP2 ACTIVITY
BR112021002327A2 (en) * 2018-08-10 2021-05-04 Navire Pharma, Inc. 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4,5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h) derivatives -one and related compounds as ptpn11(shp2) inhibitors for cancer treatment
US20200115389A1 (en) 2018-09-18 2020-04-16 Nikang Therapeutics, Inc. Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
WO2020063760A1 (en) * 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
AU2019350592B2 (en) 2018-09-29 2024-09-26 Novartis Ag Process of manufacture of a compound for inhibiting the activity of SHP2
MX2021003460A (en) * 2018-09-29 2021-06-18 Novartis Ag Manufacture of compounds and compositions for inhibiting the activity of shp2.
US11179397B2 (en) 2018-10-03 2021-11-23 Gilead Sciences, Inc. Imidazopyrimidine derivatives
WO2020076723A1 (en) 2018-10-08 2020-04-16 Revolution Medicines, Inc. Shp2 inhibitor compositions for use in treating cancer
TW202028183A (en) * 2018-10-10 2020-08-01 大陸商江蘇豪森藥業集團有限公司 Nitrogen-containing heteroaryl derivative regulators, preparation method and application thereof
US12187721B2 (en) 2018-10-17 2025-01-07 Array Biopharma Inc. Protein tyrosine phosphatase inhibitors
CN117143079A (en) * 2018-11-06 2023-12-01 上海奕拓医药科技有限责任公司 Spiro aromatic ring compound and application thereof
CA3120791A1 (en) 2018-11-30 2020-06-04 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine and five-membered nitrogen heterocycle derivative, preparation method therefor, and medical uses thereof
EA202190630A1 (en) 2018-12-05 2021-10-11 Мирати Терапьютикс, Инк. COMBINED THERAPY METHODS
MX2021010319A (en) 2019-03-01 2021-12-10 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof.
KR20210146288A (en) 2019-03-01 2021-12-03 레볼루션 메디슨즈, 인크. Bicyclic heterocyclyl compounds and uses thereof
CN111647000B (en) * 2019-03-04 2021-10-12 勤浩医药（苏州）有限公司 Pyrazine derivative and application thereof in inhibition of SHP2
WO2020181283A1 (en) 2019-03-07 2020-09-10 Merck Patent Gmbh Carboxamide-pyrimidine derivatives as shp2 antagonists
BR112021018664A2 (en) 2019-04-02 2021-11-23 Array Biopharma Inc Protein tyrosine phosphatase inhibitors
JP7586834B2 (en) 2019-04-08 2024-11-19 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyrimidinone Derivatives as SHP2 Antagonists
EP3972695A1 (en) 2019-05-23 2022-03-30 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
JP7295283B2 (en) 2019-06-25 2023-06-20 ギリアード サイエンシーズ， インコーポレイテッド FLT3L-FC fusion proteins and methods of use
EP3991731A4 (en) * 2019-06-28 2022-07-20 Tuojie Biotech (Shanghai) Co., Ltd. Pyrimidine five-membered nitrogen heterocyclic derivative, preparation method thereof and pharmaceutical use thereof
CN111704611B (en) * 2019-07-25 2022-01-14 上海凌达生物医药有限公司 Aryl spiro SHP2 inhibitor compound, preparation method and application
EP3772513A1 (en) 2019-08-09 2021-02-10 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening Shp2 inhibitors
GB201911928D0 (en) * 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
WO2021043077A1 (en) * 2019-09-06 2021-03-11 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compound and preparation method therefor and use thereof
US11890281B2 (en) 2019-09-24 2024-02-06 Relay Therapeutics, Inc. SHP2 phosphatase inhibitors and methods of making and using the same
CN112724145A (en) * 2019-10-14 2021-04-30 杭州雷索药业有限公司 Pyrazine derivatives for inhibiting SHP2 activity
EP4045083B1 (en) 2019-10-18 2024-01-10 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
NZ786589A (en) 2019-10-31 2025-03-28 Forty Seven Llc Anti-cd47 and anti-cd20 based treatment of blood cancer
US11608346B2 (en) 2019-11-04 2023-03-21 Revolution Medicines, Inc. Ras inhibitors
US11566007B2 (en) 2019-11-04 2023-01-31 Revolution Medicines, Inc. Ras inhibitors
EP4054720A1 (en) 2019-11-04 2022-09-14 Revolution Medicines, Inc. Ras inhibitors
EP4620531A3 (en) 2019-11-08 2025-11-26 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
TWI778443B (en) 2019-11-12 2022-09-21 美商基利科學股份有限公司 Mcl1 inhibitors
JP2023505100A (en) 2019-11-27 2023-02-08 レボリューション メディシンズ インコーポレイテッド Covalent RAS inhibitors and uses thereof
CN117736207A (en) 2019-12-24 2024-03-22 卡尔那生物科学株式会社 Diacylglycerol kinase modulating compounds
WO2021142026A1 (en) 2020-01-07 2021-07-15 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
CN113135910A (en) * 2020-01-19 2021-07-20 北京诺诚健华医药科技有限公司 Pyrimidine-4 (3H) -ketone heterocyclic compound, preparation method and pharmaceutical application thereof
TWI832035B (en) 2020-02-14 2024-02-11 美商基利科學股份有限公司 Antibodies and fusion proteins that bind to ccr8 and uses thereof
IL295678A (en) 2020-02-28 2022-10-01 Novartis Ag A triple pharmaceutical combination containing davarfenib, an erk inhibitor and a shp2 inhibitor
CN115362149B (en) * 2020-04-26 2024-05-14 贝达药业股份有限公司 SHP2 inhibitor, composition and application thereof
CN115279749B (en) * 2020-04-30 2024-05-10 贝达药业股份有限公司 SHP2 inhibitor, composition and application thereof
MX2022013619A (en) 2020-05-01 2022-11-16 Gilead Sciences Inc 2,4-DIOXOPYRIMIDINE COMPOUNDS THAT INHIBIT CD73.
CN113754683A (en) 2020-06-05 2021-12-07 上海奕拓医药科技有限责任公司 Isotopically substituted spiroaromatic ring compounds and their use
TW202214253A (en) 2020-06-18 2022-04-16 美商銳新醫藥公司 Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
CN115667239B (en) * 2020-06-22 2025-11-18 四川科伦博泰生物医药股份有限公司 Substituted pyrazine compounds, pharmaceutical compositions comprising them, and their uses
CN115916786B (en) 2020-07-08 2025-10-17 诺华股份有限公司 Manufacture of compounds and compositions for inhibiting SHP2 activity
IL301062A (en) 2020-09-03 2023-05-01 Revolution Medicines Inc Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
CR20230165A (en) 2020-09-15 2023-06-02 Revolution Medicines Inc Indole derivatives as ras inhibitors in the treatment of cancer
AR124449A1 (en) 2020-12-22 2023-03-29 Qilu Regor Therapeutics Inc SOS1 INHIBITORS AND USES THEREOF
EP4039685A1 (en) 2021-02-08 2022-08-10 Irbm S.P.A. Azabicyclic shp2 inhibitors
US20240025924A1 (en) * 2021-03-23 2024-01-25 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Heterocycle substituted ketone derivative, and composition and medicinal use thereof
EP4067358A1 (en) 2021-04-02 2022-10-05 C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
CR20230558A (en) 2021-05-05 2024-01-24 Revolution Medicines Inc RAS INHIBITORS FOR CANCER TREATMENT
MX2023013062A (en) 2021-05-05 2023-11-15 Huyabio Int Llc Shp2 inhibitor monotherapy and uses thereof.
AU2022271243A1 (en) 2021-05-05 2023-11-30 Huyabio International, Llc Combination therapies comprising shp2 inhibitors and pd-1 inhibitors
CN118561952A (en) 2021-05-05 2024-08-30 锐新医药公司 RAS inhibitors
CN117500811A (en) 2021-05-05 2024-02-02 锐新医药公司 Covalent RAS inhibitors and their uses
JP7656087B2 (en) * 2021-05-13 2025-04-02 中国科学院上海薬物研究所 Heterocyclic compounds that inhibit SHP2 activity, methods for their preparation and use
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
TW202313041A (en) 2021-06-09 2023-04-01 瑞士商諾華公司 A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor.
EP4359415A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CN117480155A (en) 2021-06-23 2024-01-30 吉利德科学公司 Diacylglycerol kinase modulating compounds
TW202317100A (en) 2021-06-23 2023-05-01 瑞士商諾華公司 Pharmaceutical combinations comprising a kras g12c inhibitor and uses thereof for the treatment of cancers
CN117377671A (en) 2021-06-23 2024-01-09 吉利德科学公司 Diacylglycerol kinase modulating compounds
JP7686091B2 (en) 2021-06-23 2025-05-30 ギリアード サイエンシーズ， インコーポレイテッド Diacylglycerol kinase modulating compounds
MX2024000271A (en) * 2021-07-09 2024-01-31 Kanaph Therapeutics Inc Shp2 inhibitor and use thereof.
CN113461538A (en) * 2021-07-12 2021-10-01 无锡双启科技有限公司 Preparation method of 2-chloro-3-bromoaniline
TW202327569A (en) 2021-09-01 2023-07-16 瑞士商諾華公司 Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
JP7787991B2 (en) 2021-10-29 2025-12-17 ギリアード サイエンシーズ， インコーポレイテッド CD73 compound
US20230203202A1 (en) 2021-12-08 2023-06-29 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and 5t4
WO2023107954A1 (en) 2021-12-08 2023-06-15 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122938A1 (en) * 2021-12-28 2023-07-06 Js Innomed Holdings Ltd. Heterocyclic compounds as shp2 inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
JP2025510572A (en) 2022-03-08 2025-04-15 レボリューション メディシンズ インコーポレイテッド Methods for treating immunorefractory lung cancer
CN118369323A (en) * 2022-03-10 2024-07-19 捷思英达控股有限公司 Heterocyclic compounds as SHP2 inhibitors, compositions comprising the same, and methods of use thereof
TW202346277A (en) 2022-03-17 2023-12-01 美商基利科學股份有限公司 Ikaros zinc finger family degraders and uses thereof
AU2023240346A1 (en) 2022-03-24 2024-09-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (en) 2022-04-05 2025-03-11 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
PE20250157A1 (en) 2022-04-21 2025-01-22 Gilead Sciences Inc KRAS G12D MODULATION COMPOUNDS
IL316768A (en) 2022-05-25 2025-01-01 Ikena Oncology Inc Mek inhibitors and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN119384415A (en) 2022-07-01 2025-01-28 吉利德科学公司 CD73 compounds
EP4573095A1 (en) 2022-08-17 2025-06-25 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
EP4345101A1 (en) 2022-09-29 2024-04-03 Irbm S.P.A. Azole derivatives as shp2 inhibitors
WO2024083256A1 (en) 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 Pan-kras degrading agent, and preparation method therefor and use thereof
WO2024083258A1 (en) 2022-10-21 2024-04-25 上海领泰生物医药科技有限公司 Kras g12c degradation agent, and preparation method and use therefor
CN115677660B (en) * 2022-10-27 2024-05-03 中国药科大学 Phenylurea compounds and preparation methods, uses and pharmaceutical compositions thereof
US20240254118A1 (en) 2022-12-22 2024-08-01 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024147703A1 (en) * 2023-01-05 2024-07-11 주식회사 카나프테라퓨틱스 Shp2 inhibitor and uses thereof
AU2024241633A1 (en) 2023-03-30 2025-11-06 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
AR132338A1 (en) 2023-04-07 2025-06-18 Revolution Medicines Inc RAS INHIBITORS
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
KR20250167002A (en) 2023-04-11 2025-11-28 길리애드 사이언시즈, 인코포레이티드 KRAS modulating compounds
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20250172857A (en) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Crystalline form of RAS inhibitor
CN121079300A (en) 2023-04-21 2025-12-05 吉利德科学公司 PRMT5 inhibitors and their uses
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
WO2025034919A1 (en) 2023-08-08 2025-02-13 Quanta Therapeutics, Inc. Combination therapies with kras modulators
TW202521120A (en) * 2023-08-17 2025-06-01 大陸商北京加科思新藥研發有限公司 A Pharmaceutical Combination and Use thereof
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
TW202528315A (en) 2023-09-21 2025-07-16 美商樹線生物科學公司 Spirocyclic dihydropyranopyridine kras inhibitors
TW202530228A (en) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ras inhibitors
WO2025081291A1 (en) * 2023-10-16 2025-04-24 Canwell Biotech Limited Benzo [c] [1, 2] oxaborol-1 (3h) -ol derivatives as shp2 inhibitors, compositions and methods thereof
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025106901A1 (en) 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025245003A1 (en) 2024-05-21 2025-11-27 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3377826B2 (en) 1993-05-06 2003-02-17 ヘキスト・アクチェンゲゼルシャフト Novel compounds for use in liquid crystal compositions
ATE284690T1 (en) 1995-10-31 2005-01-15 Lilly Co Eli ANTITHRBOTIC DIAMINE
CA2361734A1 (en) 1999-01-26 2000-10-12 Andre Rosowsky Pharmaceutically active compounds and methods of use thereof
US7375125B2 (en) 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
HU230302B1 (en) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogenous aromatic ring compounds and pharmaceutical compositions containing them
JP2006503796A (en) 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン Anti-angiogenic combination therapy comprising pyridazine or a pyridine derivative
JP4467307B2 (en) 2002-02-22 2010-05-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー Pyridylsulfone derivatives as 5-HT receptor antagonists
DE10246657A1 (en) 2002-10-07 2004-04-15 Merck Patent Gmbh Chiral phenols which induce a cholesteric phase in a nematic liquid crystal and simultaneously act as a stabilizer and are useful in electro-optical displays
EP1562940B1 (en) 2002-11-18 2007-05-30 ChemoCentryx Inc Aryl sulfonamides
SE0203712D0 (en) 2002-12-13 2002-12-13 Astrazeneca Ab Novel compounds
CN1747941A (en) 2003-02-07 2006-03-15 詹森药业有限公司 HIV-inhibiting 1,2,4-triazine
CA2515544A1 (en) 2003-02-11 2004-08-26 Kemia Inc. Compounds for the treatment of viral infection
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2004099158A1 (en) 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
BRPI0412382A (en) 2003-07-08 2006-09-19 Astrazeneca Ab compound, method for the discovery of novel medicinal compounds which bind to and modulate the activity, by agonism, partial agonism, or antagonism, of the nicotinic alpha7 acetylcholine receptor, method of treatment or prophylaxis of a human disease or condition, method for treatment of jetlag, inducing smoking cessation, nicotine addiction, withdrawal, pain, and for ulcerative colitis, pharmaceutical composition, and, method of treating or preventing a condition or disorder arising from nicotinic acetylcholine receptor neurotransmission dysfunction in a mammal, and, use of a compound
US7390907B2 (en) 2003-09-30 2008-06-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
TW200528459A (en) 2004-01-06 2005-09-01 Achillion Pharmaceuticals Inc Azabenzofuran substituted thioureas; inhibitors of viral replication
KR101164541B1 (en) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 Selective kinase inhibitors
US7435831B2 (en) 2004-03-03 2008-10-14 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
CA2558211C (en) 2004-03-03 2013-09-03 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
AU2005223610B2 (en) * 2004-03-23 2008-05-29 Banyu Pharmaceutical Co., Ltd. Substituted quinazoline or pyridopyrimidine derivative
JP4865702B2 (en) 2004-05-03 2012-02-01 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド Cytokine inhibitor
BRPI0512535A (en) 2004-06-24 2008-03-25 Incyte Corp unsubstituted piperidine compounds, their compositions and methods of modulation
US20070043057A1 (en) 2005-02-09 2007-02-22 Threshold Pharmaceuticals, Inc. Lonidamine analogs
KR20070085286A (en) 2004-10-29 2007-08-27 티보텍 파마슈티칼즈 리미티드 Bicyclic pyrimidine derivatives inhibit HIV
WO2006063010A2 (en) 2004-12-08 2006-06-15 Nuada, Llc Compounds and methods of use thereof
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
ES2375395T3 (en) 2004-12-23 2012-02-29 Mallinckrodt Llc FLUORESCENT PIRAZINE DERIVATIVES AND METHOD OF USE OF THE SAME IN THE EVALUATION OF RENAL FUNCTION.
US7622583B2 (en) 2005-01-14 2009-11-24 Chemocentryx, Inc. Heteroaryl sulfonamides and CCR2
ZA200707482B (en) 2005-02-04 2008-12-31 Senomyx Inc Compounds comprising linked heteroaryl moieties and their use as novel umami flavour modifiers, tastants and taste enhancers for comestible compositions
WO2006087305A1 (en) 2005-02-16 2006-08-24 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
WO2007046867A2 (en) 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Piperidine derivatives and their uses as therapeutic agents
RU2417985C2 (en) 2005-05-30 2011-05-10 Баниу Фармасьютикал Ко., Лтд. Novel piperidine derivatives
JP2007013804A (en) 2005-07-01 2007-01-18 Mitsubishi Electric Corp Attribute designation communication method and communication apparatus
CA2606004A1 (en) * 2005-08-02 2007-02-08 Neurogen Corporation Dipiperazinyl ketones and related analogues
KR101347102B1 (en) 2005-10-19 2014-01-03 그뤼넨탈 게엠베하 Novel vanilloid receptor ligands and their use for producing medicaments
WO2007057742A2 (en) 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
JPWO2007063868A1 (en) 2005-11-29 2009-05-07 東レ株式会社 Arylmethylene urea derivatives and uses thereof
CN101346368A (en) 2005-12-21 2009-01-14 詹森药业有限公司 Substituted pyrazinone derivatives as alpha2c-adrenoreceptor antagonists
WO2007084728A2 (en) 2006-01-19 2007-07-26 Abbott Laboratories 2-imino-benzimidazoles
CA2637024C (en) 2006-01-30 2013-05-14 Transtech Pharma, Inc. Substituted imidazole derivatives, compositions, and methods of use as ptpase inhibitors
JP2009529047A (en) 2006-03-07 2009-08-13 アレイ バイオファーマ、インコーポレイテッド Heterobicyclic pyrazole compounds and uses thereof
DE602007007206D1 (en) 2006-04-20 2010-07-29 Janssen Pharmaceutica Nv SUBSTITUTED PYRAZINONE DERIVATIVES FOR USE AS MEDICAMENTS
WO2007135131A1 (en) 2006-05-22 2007-11-29 Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives for use as a medicine
PE20081370A1 (en) 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc CERTAIN AMIDAS SUBSTITUTED, METHOD OF PREPARATION AND METHOD OF USE OF THE SAME
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
KR101114704B1 (en) 2006-10-04 2012-03-14 에프. 호프만-라 로슈 아게 Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
DE102007018150A1 (en) 2007-04-16 2008-10-23 Grünenthal GmbH Treating pain, using dual action compound or combination of compounds with affinity for both mu-opioid and vanilloid VR1-receptors, also effective e.g. against coughs or asthma
US8252803B2 (en) 2007-02-12 2012-08-28 Merck Sharp & Dohme Corp. Piperidine derivatives
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
CN101679266B (en) 2007-03-01 2015-05-06 诺华股份有限公司 PIM kinase inhibitors and methods of their use
WO2008108944A2 (en) 2007-03-01 2008-09-12 Mallinckrodt Inc. Integrated photoactive small molecules and uses thereof
WO2008112674A1 (en) 2007-03-12 2008-09-18 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
US20110130406A1 (en) 2007-09-06 2011-06-02 Array Biopharma Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
EP2197873B1 (en) 2007-09-20 2014-07-16 Irm Llc Compounds and compositions as modulators of gpr119 activity
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
CA2703471A1 (en) 2007-10-24 2009-04-30 Merck Sharp & Dohme Corp. Pyrazinyl amide t-type calcium channel antagonists
MX2010009454A (en) 2008-02-29 2010-11-25 Schering Corp Gamma secretase modulators for the treatment of alzheimer ' s disease.
CA2719538C (en) 2008-04-07 2014-03-18 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
AR071619A1 (en) 2008-05-07 2010-06-30 Galapagos Nv USEFUL FUSIONED PIRAZINE COMPOUNDS FOR THE TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
CN102203074A (en) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 Aryl GPR119 agonists and uses thereof
CN102186856B (en) 2008-08-22 2014-09-24 诺华股份有限公司 Pyrrolopyrimidines as CDK inhibitors
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
ES2397934T3 (en) 2008-12-17 2013-03-12 Amgen Inc. Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors
CA2744935A1 (en) 2008-12-19 2010-06-24 Boehringer Ingelheim International Gmbh New compounds
CN102264704B (en) 2008-12-25 2014-06-04 大正制药株式会社 Isoquinoline derivative
AU2010206614B2 (en) 2009-01-22 2015-03-26 Keybioscience Ag Treatment for obesity
WO2010086613A1 (en) 2009-01-30 2010-08-05 Betagenon Ab Compounds useful as inhibitors as ampk
US8859566B2 (en) 2009-03-13 2014-10-14 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011004162A2 (en) 2009-07-08 2011-01-13 Betagenon Ab Compounds useful as medicaments
CA2771190C (en) 2009-08-17 2020-01-21 Memorial Sloan-Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
US20120157471A1 (en) 2009-09-01 2012-06-21 Pfizer Inc. Benzimidazole derivatives
BR112012008004A2 (en) 2009-10-09 2016-03-29 Irm Llc compounds and compositions as modulators of gpr119 activity
US8759377B2 (en) 2009-11-23 2014-06-24 Vanderbilt University Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
EP2513057B1 (en) 2009-12-14 2013-09-04 Merck Patent GmbH Sphingosine kinase inhibitors
WO2011075607A1 (en) 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
CA2788355C (en) 2010-02-18 2018-03-06 Devi Reddy Gohimukkula Phenyl-heteroaryl derivatives and methods of use thereof
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
EP2563780B1 (en) 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
US20110312996A1 (en) 2010-05-17 2011-12-22 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
NZ603789A (en) 2010-05-26 2015-03-27 Sunovion Pharmaceuticals Inc Heteroaryl compounds and methods of use thereof
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
JP2013230986A (en) 2010-08-25 2013-11-14 Kyorin Pharmaceutical Co Ltd Novel hydantoin derivative and medicinal agent comprising the same as active ingredient
CN102432598A (en) 2010-09-29 2012-05-02 江苏恒瑞医药股份有限公司 Tricyclic compound, preparation method thereof and pharmaceutical application thereof
EP2640367A2 (en) * 2010-11-15 2013-09-25 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
GB201020161D0 (en) 2010-11-26 2011-01-12 Almac Discovery Ltd Pharmaceutical compounds
JP5937102B2 (en) 2010-12-14 2016-06-22 エレクトロフォレティクス リミテッド Casein kinase 1 delta (CK1 delta) inhibitor
WO2012088438A1 (en) 2010-12-22 2012-06-28 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
US20120184572A1 (en) 2011-01-13 2012-07-19 Metabolex, Inc. Aryl gpr119 agonists and uses thereof
BR112013027787A2 (en) 2011-04-29 2017-06-27 Icahn School Med Mount Sinai compounds, pharmaceutical composition, method for treating a cell proliferative disorder, method for treating a neurological disorder, methods for inhibiting one or more kinases, method for inhibiting cell proliferation of cancer cells, method for inducing cancer cell death, method for to induce apoptosis of cancer cells, method to induce apoptosis in a cell and methods to produce compounds
WO2012158784A2 (en) 2011-05-16 2012-11-22 Theodore Mark Kamenecka Modulators of the nuclear hormone receptor ror
US20120316182A1 (en) * 2011-06-10 2012-12-13 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
HK1202119A1 (en) 2011-12-12 2015-09-18 Celgene International Ii Sàrl Novel glp-1 receptor modulators
CN112029513B (en) 2012-02-22 2024-02-23 默克专利股份有限公司 Liquid-crystalline medium
GB201204985D0 (en) 2012-03-21 2012-05-02 Genentech Inc Compounds
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2841421B1 (en) 2012-04-25 2019-06-05 RaQualia Pharma Inc Amide derivatives as ttx-s blockers
BR112014027133A2 (en) 2012-05-09 2017-06-27 Basf Se compound, agricultural or veterinary composition, method for controlling invertebrate pests, plant propagating material and method for treating or protecting an animal.
WO2014000178A1 (en) 2012-06-27 2014-01-03 Merck Sharp & Dohme Corp. Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug
RU2665462C2 (en) 2012-06-27 2018-08-30 Ф. Хоффманн-Ля Рош Аг 5-azaindazole compounds and methods for use thereof
CA2882132C (en) 2012-08-16 2021-07-06 The Scripps Research Institute Kappa opioid ligands
JOP20130273B1 (en) 2012-09-11 2021-08-17 Genzyme Corp Glucosylceramide synthase inhibitors
EP2916839B1 (en) * 2012-11-09 2017-10-11 GlaxoSmithKline LLC Novel compounds as diacylglycerol acyltransferase inhibitors
MX2015011180A (en) 2013-03-15 2015-11-11 Hoffmann La Roche ARYL SULFAMIDE AND SULFAMATE DERIVATIVES AS RORc MODULATORS.
EP2968291B1 (en) 2013-03-15 2025-04-16 Pharmacosmos Holding A/S Hspc-sparing treatments for rb-positive abnormal cellular proliferation
WO2014184074A1 (en) 2013-05-15 2014-11-20 Basf Se Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)hetarylcarboxamide compounds and their use as herbicides
WO2014184014A1 (en) 2013-05-15 2014-11-20 Basf Se N-(1,2,5-oxadiazol-3-yl)carboxamide compounds and their use as herbicides
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
CN105593225B (en) 2013-06-11 2019-04-16 赛尔基因第二国际有限公司 Novel GLP-1 receptor modulators
AU2014284279A1 (en) 2013-07-03 2016-02-18 Beth Israel Deaconess Medical Center, Inc. SHP2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using SHP2 inhibitors
CN104341386A (en) * 2013-07-23 2015-02-11 中国科学院上海药物研究所 Aryl heterocycle micromolecule compounds, derivatives thereof, and preparing methods and uses of the compounds and the derivatives
WO2015016206A1 (en) 2013-07-30 2015-02-05 武田薬品工業株式会社 Heterocyclic compound
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US20150087673A1 (en) 2013-09-26 2015-03-26 Rigel Pharmaceuticals, Inc. Methods for using and biomarkers for ampk-activating compounds
WO2015051458A1 (en) 2013-10-08 2015-04-16 Lu qing-bin Non-platimun-based anti-cancer compounds for use in targeted chemotherapy
HUE044683T2 (en) 2013-10-21 2019-11-28 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
KR20150070027A (en) 2013-12-16 2015-06-24 메르크 파텐트 게엠베하 Liquid-crystalline medium
EP3083610A1 (en) 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
JO3517B1 (en) 2014-01-17 2020-07-05 Novartis Ag N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2
WO2015107493A1 (en) * 2014-01-17 2015-07-23 Novartis Ag 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2
ES2699354T3 (en) * 2014-01-17 2019-02-08 Novartis Ag Derivatives of 1- (triazin-3-yl / pyridazin-3-yl) -piper (-azin) idine and compositions thereof to inhibit the activity of SHP2
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
AU2015218402B2 (en) 2014-02-14 2019-07-11 Takeda Pharmaceutical Company Limited Pyrazines modulators of GPR6
US10000469B2 (en) 2014-03-25 2018-06-19 Duke University Heat shock protein 70 (hsp-70) receptor ligands
RU2692479C2 (en) 2014-04-07 2019-06-25 Недерлэндс Транслэшинал Рисерч Сентер Б.В. (5,6-dihydro)pyrimido[4,5-e]indolysines
EP3145912A1 (en) 2014-05-23 2017-03-29 F. Hoffmann-La Roche AG Benzene sulfonamide derivatives and their use as rorc modulators
WO2016015605A1 (en) 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
WO2016022644A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
WO2016022645A1 (en) 2014-08-06 2016-02-11 Merck Sharp & Dohme Corp. Heterocyclic cgrp receptor antagonists
EP2985334B1 (en) 2014-08-15 2018-06-20 Merck Patent GmbH Liquid-crystalline medium
CN107074787B (en) * 2014-09-05 2020-10-27 赛尔基因昆蒂赛尔研究公司 Inhibitors of lysine-specific demethylase-1
WO2016040449A1 (en) 2014-09-10 2016-03-17 Raze Therapeutics, Inc. 3-phosphoglycerate dehydrogenase inhibitors and uses thereof
EP3262049B1 (en) 2015-02-27 2022-07-20 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
AU2016228660B2 (en) 2015-03-11 2020-05-07 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug
CN107787226A (en) 2015-03-25 2018-03-09 诺华股份有限公司 Drug regimen
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AR104020A1 (en) 2015-06-04 2017-06-21 Kura Oncology Inc METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS
JP6878316B2 (en) 2015-06-19 2021-05-26 ノバルティス アーゲー Compounds and compositions for inhibiting the activity of SHP2
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
US10287266B2 (en) 2015-06-19 2019-05-14 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
RU2604047C1 (en) 2015-07-10 2016-12-10 Фортис Аксис, Закрытое Акционерное Общество Masseur for back muscles exercising three vertebral parts
IL257743B (en) 2015-09-17 2022-08-01 Marvin J Miller Heterocyclic compounds containing benzyl amine and preparations useful against mycobacterial inflammation
WO2017114351A1 (en) 2015-12-27 2017-07-06 Chongqing Fochon Pharmaceutical Co., Ltd. Certain protein kinase inhibitors
WO2017156397A1 (en) 2016-03-11 2017-09-14 Board Of Regents, The University Of Texas Sysytem Heterocyclic inhibitors of ptpn11
US10570141B2 (en) 2016-03-25 2020-02-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Substituted pyrrolopyrimidine CDK inhibitor, pharmaceutical composition containing same and use thereof
CN107286150B (en) 2016-04-11 2020-07-07 中国科学院上海有机化学研究所 N-heterocyclic compounds, their intermediates, preparation methods, pharmaceutical compositions and applications
WO2017210134A1 (en) 2016-05-31 2017-12-07 Board Of Regents, University Of Texas System Heterocyclic inhibitors of ptpn11
CN114539273A (en) * 2016-06-07 2022-05-27 北京加科思新药研发有限公司 Novel heterocyclic derivatives useful as SHP2 inhibitors
WO2017216706A1 (en) 2016-06-14 2017-12-21 Novartis Ag Compounds and compositions for inhibiting the activity of shp2
WO2018013597A1 (en) 2016-07-12 2018-01-18 Revolution Medicines, Inc. 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
EP3290412A1 (en) 2016-08-31 2018-03-07 Università degli Studi di Siena Hiv-1 nucleocapsid inhibitors
WO2018057884A1 (en) 2016-09-22 2018-03-29 Relay Therapeutics, Inc. Shp2 phosphatase inhibitors and methods of use thereof
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
EP3565810A1 (en) 2017-01-03 2019-11-13 ViiV Healthcare UK (No.5) Limited Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
RU2769132C2 (en) * 2017-01-10 2022-03-28 Новартис Аг Pharmaceutical combination containing alk inhibitor and shp2 inhibitor
EP3573606A4 (en) * 2017-01-25 2020-11-25 Indiana University Research and Technology Corporation PROPHYLAXIS AND TREATMENT OF ACUTE MYELOIC LEUKEMIA
HRP20241239T1 (en) * 2017-03-23 2024-12-06 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
CN109803972B (en) 2017-04-01 2021-11-23 晟科药业（江苏）有限公司 1H-imidazole [4,5-H ] quinazoline compound as protein kinase inhibitor
WO2019014427A1 (en) 2017-07-12 2019-01-17 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
CN111212834B (en) 2017-10-12 2024-01-19 锐新医药公司 Pyridine, pyrazine and triazine compounds as allosteric SHP2 inhibitors
CN118063442A (en) 2017-10-20 2024-05-24 范德比尔特大学 Antagonist of the muscarinic acetylcholine receptor M4
AU2018392805A1 (en) 2017-12-22 2020-05-07 Dana-Farber Cancer Institute, Inc. NEK inhibitors and methods of use
IL312674A (en) 2018-01-29 2024-07-01 Merck Patent Gmbh Gcn2 inhibitors and uses thereof
EP3746075B1 (en) 2018-01-29 2025-09-03 Merck Patent GmbH Gcn2 inhibitors and uses thereof
WO2019152454A1 (en) 2018-01-30 2019-08-08 Research Development Foundation Shp2 inhibitors and methods of use thereof
MX2020007918A (en) 2018-02-08 2020-12-03 Enyo Pharma Fused thiophene derivatives and their uses.
JP7326305B2 (en) 2018-03-02 2023-08-15 大塚製薬株式会社 pharmaceutical compound
JP7462951B2 (en) 2018-03-21 2024-04-08 リャオ，シビン JAK inhibitors

Also Published As

Publication number Publication date
LT3464272T (en) 2022-03-10
PT3464272T (en) 2022-03-11
AU2017276457A1 (en) 2019-01-24
MA45189A (en) 2019-04-10
KR20210019607A (en) 2021-02-22
US20190127378A1 (en) 2019-05-02
EP3464272A4 (en) 2019-04-24
SI3464272T1 (en) 2022-05-31
ES2908801T3 (en) 2022-05-04
JP6751203B2 (en) 2020-09-02
PL3464272T3 (en) 2022-03-28
HRP20220251T1 (en) 2022-04-29
CN112250670A (en) 2021-01-22
KR20210141778A (en) 2021-11-23
CN109311848A (en) 2019-02-05
JP2022153616A (en) 2022-10-12
EA201990001A1 (en) 2019-05-31
HUE057838T2 (en) 2022-06-28
EP3464272B1 (en) 2021-12-08
SG10202110874TA (en) 2021-11-29
JP2020189868A (en) 2020-11-26
CA3026784A1 (en) 2017-12-14
KR20230109185A (en) 2023-07-19
DK3464272T3 (en) 2022-02-21
EP3464272A1 (en) 2019-04-10
MX2018015297A (en) 2019-08-12
MX388576B (en) 2025-03-20
EP4108659A1 (en) 2022-12-28
KR20190015756A (en) 2019-02-14
KR102218333B1 (en) 2021-02-22
MX2021015073A (en) 2022-01-18
JP2019521181A (en) 2019-07-25
EA202092442A3 (en) 2021-08-31
EA202092442A2 (en) 2021-06-30
EA202092441A1 (en) 2021-05-21
AU2017276457B2 (en) 2019-10-03
KR20220124275A (en) 2022-09-13
CN112250670B (en) 2021-06-08
WO2017211303A1 (en) 2017-12-14
PH12018550202A1 (en) 2019-10-21
CY1125042T1 (en) 2023-03-24
CN109311848B (en) 2022-02-01
RS62987B1 (en) 2022-03-31
CN114539273A (en) 2022-05-27
US10858359B2 (en) 2020-12-08
MX2021015074A (en) 2022-01-18

Similar Documents

Publication Publication Date Title
SG11201810983PA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805645QA (en) Lsd1 inhibitors
SG11201808708RA (en) Heterocyclic amides useful as protein modulators
SG11201811414TA (en) Heterocyclic compounds as immunomodulators
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201809714TA (en) Piperidines as menin inhibitors
SG11201908532UA (en) Macrocyclic compounds as ros1 kinase inhibitors
SG11201408821SA (en) Selective pi3k delta inhibitors
SG11201408750VA (en) NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201900163PA (en) Macrocycle kinase inhibitors
SG11201907356SA (en) Piperidine-substituted mnk inhibitors and methods related thereto
SG11201909376TA (en) Crystalline forms of a jak inhibitor compound
SG11201500005SA (en) Pyrimidine pyrazolyl derivatives
SG11201811686UA (en) 18f-labeled triazole containing psma inhibitors
SG11201804589TA (en) Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists
SG11201811380RA (en) Chelate compounds
SG11201903091VA (en) Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors
SG11201810940XA (en) Methods of treating pancreatic cancer